BD Libertas Wearable Injector in First Pharma-Sponsored Biologic Drug Trial

BD announces first pharma-sponsored clinical trial using BD Libertas Wearable Injector for subcutaneous delivery of biologics. This follows successful outcomes from over 50 BD-conducted pre-clinical and clinical studies. The trial represents a significant advancement in drug-device combination products, providing greater flexibility for patients. BD Libertas Wearable Injector demonstrated excellent performance in a device clinical study, with 100% of participants stating they would likely use it if prescribed.

BD (Becton, Dickinson and Company) (NYSE: BDX) has announced the first pharma-sponsored clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. This trial represents a significant advancement in drug-device combination products, providing greater flexibility for patients and the potential for more convenient patient care.

The selection of the BD Libertas™ Wearable Injector for this trial follows successful outcomes from over 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribed [1].

The BD Libertas™ Wearable Injector is an innovative, prefilled, patient-ready-to-use drug delivery system designed to enable the delivery of complex biologics via subcutaneous injection. It supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies. The device is offered in 2 to 5 mL and 5 to 10 mL configurations, providing flexibility for diverse therapeutic requirements. Its fully mechanical design features a simple "peel, stick and click" mechanism, requiring no end-user filling or assembly [1].

The biologics market is expected to grow to more than $670 billion by 2030, and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production [1].

"This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery" [1].

References:

[1] https://www.prnewswire.com/news-releases/bd-announces-first-pharma-sponsored-clinical-trial-using-bd-libertas-wearable-injector-technology-for-biologic-drugs-302511241.html